This study focuses on individuals living with Takayasu Arteritis, a rare type of vasculitis, which is an inflammation of the blood vessels. The research aims to evaluate the effectiveness and safety of secukinumab compared to standard medical treatments in patients with severe forms of this condition. The study also considers the possibility of stopping the use of prednisone, a type of steroid medication, as part of achieving long-term health.

Participants may receive secukinumab or one of several other medications used as standard care, including infliximab, tocilizumab, or adalimumab. These treatments are administered through different methods, such as intravenous administration, which involves delivering medicine directly into a vein, or subcutaneous use, which is an injection into the fatty tissue just under the skin. During the study, health status is monitored to see if the disease enters a state of remission, meaning the symptoms and signs of the illness are significantly reduced or absent.

Over the course of the study, medical professionals will observe how patients respond to these different therapies over several months. Monitoring includes checking for changes in physical symptoms and using imaging tools such as magnetic resonance imaging or computed tomography to look at the blood vessels. The process tracks how well the medications work to control inflammation and whether patients can maintain their health without the continuous use of steroids.